Navigation Links
Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
Date:11/7/2012

JERUSALEM, Israel, November 6, 2012 Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012. QNASL is a recently approved "dry" nasal aerosol corticosteroid that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

Findings from one clinical study being presented at the meeting highlight the nasal symptom improvement and efficacy profile of QNASL in children ages 6-11 with seasonal allergic rhinitis (SAR), while others reinforce ocular safety, appropriate dosing and device performance.

On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL. The product became available to patients by prescription in April 2012, making it the first marketed nonaqeous or "dry" nasal aerosol product in a category that reports annual sales of $2.5 billion. QNASL is delivered as a once-daily, nonaqueous aerosol that uses an environmentally friendly propellant (HFA) and contains a built-in dose counter.

"QNASL has provided an alternative therapy for patients suffering from allergic rhinitis," said Dr. William Storms, MD, practicing allergist, clinical professor at the University of Colorado Health Sciences Center and founder of the William Storms Allergy Clinic in Colorado Springs, CO. "The dry mode of delivery of QNASL, along with the performance and functionality of the device, offers patients a safe and effective way to manage and control their nasal allergy symptoms. The data to be presented at ACAAI this year further demonstrate the efficacy profile of QNASL, especially among the pediatric population and confirm the product's ocular safety profile in adolescents and adults."

The following QNASL (beclomethasone dipropionate) data will be presented during poster sessions on Saturday, November 10 from 12:30 1:30 p.m. PST and Sunday, November 11 from 12:00 1:00 p.m. PST in Hall C (first floor) of the Anaheim Convention Center at the ACAAI Annual Meeting:

  • #P314: Device and Integrated Dose Counter Performance of Beclomethasone Dipropionate Nasal Aerosol During Daily Use

  • #P329: Nasal Symptom Improvement Following Once-Daily Treatment With Beclomethasone Dipropionate Nasal Aerosol (80 g or 160 g) in Children With Seasonal Allergic Rhinitis

  • #P330: Efficacy, Safety, and Optimal Dose Selection of Beclomethasone Dipropionate Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

  • #P331: Evaluation of Ocular Safety Following Long-Term Treatment With Beclomethasone Dipropionate Nasal Aerosol in Subjects With Perennial Allergic Rhinitis

  • #P325: Nasal Deposition of Beclomethasone Dipropionate Nasal Aerosol Versus Fluticasone Propionate and Mometasone Furoate Aqueous Nasal Sprays

"The data to be presented at ACAAI provide additional evidence that QNASL is a generally well-tolerated and effective treatment option for people suffering with seasonal and year-round nasal allergies," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "We are committed to the development of novel therapies to help the millions of Americans who suffer from allergic rhinitis effectively manage and control their burdensome symptoms."


'/>"/>
Contact: Denise Bradley
denise.bradley@tevapharm.com
215-591-8974
Teva North America


Source:Eurekalert


Related medicine news :

1. Medical care presents update on pharmaceutical health services research
2. Results of the STEMI-RADIAL trial presented at TCT 2012
3. Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
4. Results of the XIMA trial presented at TCT 2012
5. Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
6. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
7. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
8. Results of the PC trial presented at TCT 2012
9. Results of the POSEIDON trial presented at TCT 2012
10. 1-year results of ADAPT-DES presented at TCT 2012
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... on patients with cancer, has added Cancer and Careers to its ... more timely content on continuing successful careers while fighting cancer. , As partners, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... within Final Cut Pro X. Choose from abstract transitions to more simple wipes ...
(Date:5/30/2016)... Texas (PRWEB) , ... May 30, 2016 , ... Another ... 7 am in Plano, located at 3960 Legacy Drive, Plano, TX and is open ... Plano Chamber of Commerce followed by a medical open house. The Jasper High School ...
(Date:5/29/2016)... Viejo, CA (PRWEB) , ... May 29, 2016 , ... ... Volume 3 let's the user control the style of their project," said Christina Austin ... set of 30 self-animating web-themed intros created exclusively for use in Final Cut Pro ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... -- , Isansys  Lifecare, a new generation digital ... wireless patient monitoring platform, as it ships more systems to ... , Scotland and Norway ... system, launched earlier this year, is now being used in ... This new technology significantly enhances the user experience and ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
Breaking Medicine Technology: